Corrigendum: A Mini-Review of Pharmacological and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD(Front. Psychiatry, (2022), 13, (794044), 10.3389/fpsyt.2022.794044)

In the original article, we mistakenly reported on a secondary outcome for the Towbin et al. (2020) study, specifically the Children’s Depression Rating Scale—Irritability item rather than the primary outcome, the Clinical Global Impression’s for Chronic Severe Irritability. We have updated this information to Table 1; the corrected Table 1 appears below. An update has been made to the “Pharmacological Interventions” section, at the end of paragraph 2:The original text “A significant decrease in irritability was observed from baseline to the endof the 5-week open trial on MPH (d = 0.69, p < 0.001); however, a non-significant difference was observed between the citalopram and placebo groups for change in irritability during the subsequent blinded randomized trial phase (18)” has been replaced by “For their primary outcome of the Clinical Global Impression’s for Chronic Severe Irritability, a significant decrease inirritability was found (d = 0.60), with the estimated response differing between the citalopram(35%) and placebo (6%) groups (OR = 1.70, p = 0.006) (18).” This has resulted in updates to several places in the Discussion section.